These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27426244)

  • 1. [Evidence on afatinib in patients progressing on a first-line treatment].
    Artal Cortés Á; Gimeno Pelegrín J; Alejandro MÁ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():19-24. PubMed ID: 27426244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
    Taus Á
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA; Kolesar JM
    Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    Sárosi V; Balikó Z
    Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
    PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
    Hata A; Katakami N; Kaji R; Yokoyama T; Kaneda T; Tamiya M; Inoue T; Kimura H; Yano Y; Tamura D; Morita S; Negoro S; The Hanshin Oncology Group F
    Cancer; 2018 Oct; 124(19):3830-3838. PubMed ID: 30192383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P; González AL; García-Palomo A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
    Janjigian YY; Smit EF; Groen HJ; Horn L; Gettinger S; Camidge DR; Riely GJ; Wang B; Fu Y; Chand VK; Miller VA; Pao W
    Cancer Discov; 2014 Sep; 4(9):1036-45. PubMed ID: 25074459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
    Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
    Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
    Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
    Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Afatinib (BIBW 2992)].
    Prim N; Fore M; Mennecier B
    Rev Pneumol Clin; 2014 Oct; 70(5):279-85. PubMed ID: 24878189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W; Tufman A; Huber RM
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.